AstraZeneca's (AZN) TAGRISSO demonstrated strong OS benefit in ADAURA Phase III trial for adjuvant treatment of patients with early-stage EGFR-mutated lung cancer
Positive high-level results from the ADAURA Phase III trial showed…
Elana Gotkine
MONDAY, Nov. 21, 2022 (HealthDay News) -- For patients with systemic lupus erythematosus (SLE), anifrolumab is safe in the long term, according to a study published online Nov. 11 in…
Manassas, VA, June 29, 2022 (GLOBE NEWSWIRE) -- Notal Vision, Inc. reported today that numerous scientific and clinical publications and presentations prove the feasibility and efficacy of their patient-operated, home-based optical…
One cycle of IMX-110 produced 75% survival vs. 0% survival for Trabectedin (sold as YONDELIS ® by Janssen, a Johnson & Johnson Company, a U.S. FDA approved drug)In a connective tissue cancer Soft Tissue Sarcoma (STS) mice study,…
Since the first sequencing of the human genome more than 20 years ago, the study of human genomes has relied almost exclusively on a single reference genome to which others are compared to identify genetic variations. Scientists have long…
LONDON and RALEIGH, N.C., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, today announces ensifentrine met all safety…
In a recent phase 2b/3 clinical trial, a third mRNA vaccine against COVID-19 -- known as CVnCoV and developed by CureVac -- reported approximately 48 percent efficacy against symptomatic disease. In a head-to-head test of a revised version…